Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Robert Rennaker
University of Texas Dallas, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Teliatry, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Teliatry is commercializing a nerve stimulation system that incorporates technology created at UTD. Teliatry has a nonexclusive license for UTD technology incorporated into the devices. This project is related to Dr. Rennaker’s financial interest in Teliatry because the outcome of the research project could affect the financial interests of Teliatry.
Dr. Rennaker’s financial interest in Teliatry could significantly and directly affect the conduct of this research project because this PHS project will use devices purchased from Teliatry. Teliatry is not pursuing clinical studies of their device to treat specific disorders.
Wireless Nerve Stimulation Device To Enhance Recovery After Stroke
PROJECT NARRATIVE Vagus nerve stimulation (VNS) has the potential to transform rehabilitation for stroke, but successful translation of this therapy is limited by the cost, size, power consumption, lead fragility, and technical features of commercially available VNS devices. We have developed a novel wireless, lead-less, low-cost clinical grade device to obviate these challenges. Here, we propose to finalize testing to meet FDA regulatory standards and perform a first-in-human clinical study that will lead directly to a pivotal clinical study.
Filed on March 01, 2019.
Tell us what you know about Robert Rennaker's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.